Industry
Biotechnology
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
5.02
Mkt cap
254M
Volume
43K
High
5.04
P/E Ratio
-1.53
52-wk high
6.40
Low
4.88
Div yield
N/A
52-wk low
1.53
Portfolio Pulse from Vandana Singh
June 27, 2024 | 5:17 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 8:12 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 8:12 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 7:08 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 11:08 am
Portfolio Pulse from Vandana Singh
April 19, 2024 | 1:28 pm
Portfolio Pulse from Charles Gross
April 09, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 10:12 pm
Portfolio Pulse from Vandana Singh
April 05, 2024 | 5:37 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.